Comparison of the post-meal glucose response to different insulin bolus waveforms in insulin pump- and pre-meal pramlintide-treated type 1 diabetes patients

Diabetes Technology and Therapeutics

Volumn 12, Issue 2, 2010, Pages 105-108

  King, Allen B ^a  

^a Diabetes Care Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; PRAMLINTIDE;

ARTICLE; BLOOD GLUCOSE MONITORING; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEVICE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; MALE; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WAVEFORM;

ADULT; ALGORITHMS; AMYLOID; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD;

EID: 76449099133     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2009.0096     Document Type: Article

References (12)

1. American Diabetes Association: Standards of medical care in diabetes. Diabetes Care 2009;32(Suppl 1):S13-S61.
2. American Association of Clinical Endocrinologists: Consensus statement on guidelines for glycemic control. Endocr Pract 2002;8(Suppl 1):5-11.
3. A desktop guide to type 2 diabetes: European Diabetes Policy Group. Diabet Med 1999;16:716-730.
4. Fineman MS, Koda JE, Shen LZ, Strobel SA, Maggs DG, Weyer C, Kolterman OG: The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 2002;51:636-641. (Pubitemid 34516520)
5. Kong M-F, Stubbs TA, King P, Macdonald IA, Lambourne JE, Blackshaw PE, Perkins AC, Tattersall RB: The effect of single doses of pramlintide on gastric emptying of two meals in mean with IDDM. Diabetologia 1998;41:577-582.
6. Chase HP, Saib SZ, MacKenzie T, Hansen MM, Garg SK: Post-prandial glucose excursions following four methods of bolus insulin administration in subjects with type 1 diabetes. Diabet Med 2002;19:317-321.
7. Pankowska E, Szypowska A, Lipka M, Szpotanska M, Blazik M, Groele L, Golicka D: Three kind of mealtime insulin administration and metabolic control in diabetic children on insulin pumps [abstract 948-P]. Diabetologia 2008;51 (Suppl 1):S281.
8. Edelman S, Garg S, Frias J, Maggs D, Yang Y, Zhang B, Strobel S, Lutz K, Kolterman O: A double-blind, placebocontrolled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 2006;29:2189-2195.
9. Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Yang Y, Ruggles JA, Kolterman OG, Maggs DG: Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care 2003;26: 3074-3079.
10. King AB, Genta F, Wolfe GS: A modified combination wave versus a square wave insulin bolus compared using continuous glucose monitoring in pump and pramlintide treated type 1 diabetes [abstract 549-P]. Diabetes 2009;58 (Suppl 1):A120.
11. Heptulla RA, Rodriguez LM, Bomgaars L, Haymond MW: The role of amylin and glucagon in the dampening glycemic excursions in children with type 1 diabetes. Diabetes 2005;54:1100-1107.
12. Ceriello A, Piconi L, Quagliaror L, Yang Y, Schnabel CA, Ruggles JA, Gloster MA, Maggs DG, Weyer C: Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. Diabetes Care 2005;28:632-637. (Pubitemid 40315324)